Publications

5600 Results

SWOG 1904: Cluster-randomized controlled trial of patient and provider decision support to increase chemoprevention informed choice among women with atypical hyperplasia or lobular carcinoma in situ (MiCHOICE)

Authors
K Crew;G Anderson;K Arnold;A Stieb;J Amenta;C Law;A Sandoval-Leon;S Colonna;T King;D Mangino;S Pruthi;M Grosse-Perdekamp;C Braun-Inglis;S Krisher;L Lee;D Bertoni;S Seaward;T Ballinger;K Wisinski;J Floyd;C Zarwan;L VanderWalde;M Ross;P Steen;S Lo;A Conlin;K Yost;J Ellerton;E Lin;H Pederson;S Sardesai;S Sardesai;C Jernigan;D Hershman;M Neuhouser;B Arun;Rita Kukafka
Journal / Conference
San Antonio Breast Cancer Symposium (December 6-10, 2022, San Antonio, TX), poster, trials in progress
Year
2022
Research Committee(s)
Prevention, Screening, and and Surveillance
Study Number(s)
S1904

Incidence of Chemotherapy Induced Peripheral Neuropathy in Patients with Early-Stage Breast Cancer Receiving Taxane Therapy: SWOG S1714 (NCT# 03939481)

Authors
M Trivedi;J Unger;D Hershman;A Darke;D Hertz;T Brannagan;S Smith;B Schneider;W Irvin;A Hathaway;A Vander Woude;V Gudena;NL Henry;M Fisch
Journal / Conference
Cancer Research Vol 83, Issue 5_Suppl 1 March 2023; San Antonio Breast Cancer Symposium (Dec 6-10, 2022, San Antonio, TX, Spotlight Poster Discussion
Year
2022
Research Committee(s)
Symptom Management and Survivorship
Study Number(s)
S1714

Race and Clinical Outcomes in the RxPONDER Trial (SWOG S1007)

Authors
Y Abdou;W Barlow;J Gralow;F Meric-Bernstam;K Albain;D Hayes;N Lin;E Perez;L Goldstein;S Chia;S Dhesy-Thind;P Rastogi;E Alba;S Delaloge;A Schott;S Shak;P Sharma;D Lew;J Miao;D Tripathy;L Pusztai;G Hortobagyi;K Kalinsky
Journal / Conference
San Antonio Breast Cancer Symposium (Dec 6-10, 2022, San Antonio, TX), oral
Year
2022
Research Committee(s)
Breast
Study Number(s)
S1007

Impact of HER2 low status on clinical outcomes in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): results from SWOG S1007 (RxPONDER)

Authors
L Spring;W Barlow;A Bardia;P Sharma;L Pusztai;G Hortobagyi;K Kalinsky
Journal / Conference
San Antonio Breast Cancer Symposium (Dec 6-10, 2022, San Antonio, TX), poster
Year
2022
Research Committee(s)
Breast
Study Number(s)
S1007

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Disease

Authors
S Patel;M Othus;YK Chae;M Dennis;S Gordon;B Tan;W Samlowski;E Sharon;C Ryan;M Plets;CD Blanke;R Kurzrock
Journal / Conference
Society for Immunotherapy of Cancer (SITC) (Nov 8-12,2022, Boston, MA), poster
Year
2022
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609

Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma

Authors
D Luan;Z Chen;L Jakobsen;M Maurer;T El-Galaly;L Nastoupil;J Cerhan;C Flowers;B Link;I Lossos;D Stephens;T Habermann;G Nowakowski;N Bartlett;J Friedberg;B Kahl;J Leonard;K Smedby;M Jerkeman;P Martin
Journal / Conference
ASH Annual Meeting (Dec 10 thru 13, 2022, New Orleans, LA), oral
Year
2022
Research Committee(s)
Lymphoma
Study Number(s)
CTSU/E1412, E4494, S1001

Intervention non-adherence in a pragmatic randomized trial of a standardized order entry for colony stimulating factor prescribing

Authors
D Hershman;A Bansal;W Barlow;K Arnold;A Bell-Brown;K Watabayashi;K Kreizeneck;S Sullivan;G Lyman;S Ramsey
Journal / Conference
ASCO Quality Care Symposium (September 30 - October 1, 2022, Chicago, IL), oral presentation
Year
2022
Research Committee(s)
Cancer Care Delivery
Study Number(s)
S1415CD

How many stratification factors are reasonable and can there be too many? Evaluation of analysis strategies in the context of a randomized Phase 2 trial in acute myeloid leukemia within the myeloMATCH platform

Authors
A Moseley;B Freidlin;R Shallis;A Zeidan;D Sallman;R Little;H Erba;M LeBlanc;M Othus
Journal / Conference
ASH Annual Meeting (Dec 10 thru 13, 2022, New Orleans, LA), poster
Year
2022
Research Committee(s)
Leukemia
Study Number(s)
MYELOMATCH

Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411

Authors
M Smith;O Jegede;P Martin;B Till;S Parekh;D Yang;L Kostakoglu Shields;C Casulo;N Bartlett;P Caimi;T Al Baghdadi;K Maddocks;M Romer;D Inwards;R Lerner;L Wagner;R Little;JW Friedberg;J Leonard;B Kahl
Journal / Conference
ASH Annual Meeting (Dec 10 thru 13, 2022, New Orleans, LA), oral presentation
Year
2022
Research Committee(s)
Lymphoma
Study Number(s)
CTSU/E1411

RANDOMIZED PHASE II TRIAL OF NEOADJUVANT GEMCITABINE, AVELUMAB AND CARBOPLATIN VS. NO NEOADJUVANT THERAPY PRECEDING SURGERY FOR CISPLATIN-INELIGIBLE MUSCLE-INVASIVE UROTHELIAL CARCINOMA (MIUC): SWOG GAP TRIAL (S2011)

Authors
G Sonpavde;M Plets;M Liss;J Meeks;D Petrylak;S Cole;R McKay;S Gupta;T Pereira;R Bangs;C Tangen;IM Thompson;SP Lerner
Journal / Conference
Society of Urologic Oncology (Nov 30, 2022 - Dec 02, 2022, San Diego, CA), poster
Year
2022
Research Committee(s)
Genitourinary
Study Number(s)
S2011